Nexalin Technology, Inc. WarrantNXLIW
About: Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
Employees: 7
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0% more funds holding
Funds holding: 6 [Q4 2024] → 6 (+0) [Q1 2025]
0.46% less ownership
Funds ownership: 7.76% [Q4 2024] → 7.3% (-0.46%) [Q1 2025]
49% less capital invested
Capital invested by funds: $384K [Q4 2024] → $195K (-$188K) [Q1 2025]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for NXLIW.
Financial journalist opinion
We haven’t received any recent news articles for NXLIW.